# Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer

> **NCT00082862** · PHASE2 · UNKNOWN · sponsor: **The University of Texas Health Science Center, Houston** · enrollment: 48 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** recombinant interferon alfa
- **DRUG:** cisplatin
- **DRUG:** gemcitabine hydrochloride
- **PROCEDURE:** hyperthermia treatment

## Key facts

- **NCT ID:** NCT00082862
- **Lead sponsor:** The University of Texas Health Science Center, Houston
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2002-07
- **Primary completion:** 2012-11
- **Final completion:** —
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2012-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00082862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00082862, "Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00082862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*